Top

CardioVascular and Interventional Radiology

Published in:

01-01-2019 | Laboratory Investigation

Feasibility of Helical I-125 Seed Implant in the Portal Vein

Authors: Chen Wang, Wansheng Wang, Jian Shen, Baosheng Ren, Xiaoli Zhu, Caifang Ni

Published in: CardioVascular and Interventional Radiology | Issue 1/2019

Abstract

Purpose

To evaluate the feasibility of helical iodine-125 (I-125) seed portal vein implantation.

Materials and Methods

Helical I-125 seed implants were placed into the portal vein of healthy pigs through the transjugular (n = 3) or percutaneous transhepatic (n = 3) route. Six pigs received follow-up at 9 weeks after implantation. Blood tests were performed preimplantation, and at 1 and 9 weeks after implantation. Contrast-enhanced computed tomography (CT) and single-photon emission computed tomography combined with CT (SPECT-CT) were acquired after implantation. Post-implantation CT was imported to the treatment planning system (TPS) for dose verification. At 9 weeks after implantation, another CT was performed before histopathological examination.

Results

All implantations were successful, and the helical implants were fixed to the portal vein. CT showed no implant migration or portal vein thrombosis. The average dose to 90% of the target volume calculated from TPS was 68.4 Gy. SPECT-CT revealed an irregular isodose around the implant, in which the hottest spot was near the central portal vein lumen. All pigs were in good condition at the 9-week follow-up. Histopathology studies confirmed no portal vein thrombosis. Pigs showed no signs of bleeding, necrosis, or perforation of the peripheral tissue or organs. Intimal hyperplasia was observed at the two ends of the implant. A mild inflammatory response was detected in the bile duct and adjacent liver tissues, yet there was no apparent inflammation of the hepatic arteries.

Conclusion

The helical I-125 seed implants can be inserted into the portal veins of healthy pigs.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12(47):7561–7.CrossRef

Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, Md). 1999;29(1):62–7. https://doi.org/10.1002/hep.510290145.CrossRef

Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology (Baltimore, Md). 2000;32(2):233–8. https://doi.org/10.1053/jhep.2000.9603.CrossRef

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/s1470-2045(08)70285-7.CrossRefPubMed

Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, et al. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016;279(2):630–40. https://doi.org/10.1148/radiol.2015150667.CrossRefPubMed

Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458–67. https://doi.org/10.1002/ijc.29126.CrossRefPubMed

Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2016;22(30):6851–63. https://doi.org/10.3748/wjg.v22.i30.6851.CrossRefPubMedPubMedCentral

10.

Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, et al. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26(10):3428–36. https://doi.org/10.1007/s00330-015-4198-x.CrossRefPubMedPubMedCentral

11.

Luo JJ, Zhang ZH, Liu QX, Zhang W, Wang JH, Yan ZP. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hep Intl. 2016;10(1):185–95. https://doi.org/10.1007/s12072-015-9663-8.CrossRef

12.

Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience. JVIR. 2017;28(6):786–94.e3. https://doi.org/10.1016/j.jvir.2017.02.014.CrossRefPubMed

13.

Zhang FJ, Li CX, Jiao DC, Zhang NH, Wu PH, Duan GF, et al. CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. Chin Med J. 2008;121(23):2410–4.PubMed

14.

Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. Journal of vascular and interventional radiology: JVIR. 2011;22(4):479–89. https://doi.org/10.1016/j.jvir.2010.11.029.CrossRefPubMed

15.

Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, et al. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140(2):211–9. https://doi.org/10.1007/s00432-013-1568-0.CrossRefPubMed

16.

Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, et al. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget. 2017;8(7):12108–19. https://doi.org/10.18632/oncotarget.14520.CrossRefPubMedPubMedCentral

17.

Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15:612–9.CrossRef

18.

Zhu HD, Guo JH, Zhu GY, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. J Hepatol. 2012;56:1104–11.CrossRef

19.

Yao LH, Su L, Liu L, Sun HT, Wang JJ. Stenting of the Portal Vein Combined with Different Numbers of Iodine-125 Seed Strands: Dosimetric Analyses. Chin Med J. 2017;130(18):2183–9. https://doi.org/10.4103/0366-6999.213974.CrossRefPubMedPubMedCentral

Title: Feasibility of Helical I-125 Seed Implant in the Portal Vein
Authors: Chen Wang
Wansheng Wang
Jian Shen
Baosheng Ren
Xiaoli Zhu
Caifang Ni
Publication date: 01-01-2019
Publisher: Springer US
Published in: CardioVascular and Interventional Radiology / Issue 1/2019
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-018-2059-0

At a glance: The STEP trials

Springer Medicine

Feasibility of Helical I-125 Seed Implant in the Portal Vein

Abstract

Purpose

Materials and Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Establishing a Platform for Interest and Education in Interventional Radiology Amongst Radiology Trainees

Introducing the New 3.5/28 Microstent Retriever for Recanalization of Distal Cerebral Arteries in Acute Stroke: Preliminary Results

Factors Associated with Secondary Functional Patency After Percutaneous Transluminal Angioplasty of the Early Failing or Immature Hemodialysis Arteriovenous Fistula

Fluoroscopy-Guided Peroral Placement of a Self-Expandable Metallic Stent for Malignant Jejunal Obstruction in a Non-surgically Altered Stomach

Which G-Tube to Use in Pullers: Assessment of Pull Pressures on Skin Models to Determine Optimal Catheter Choice in Patients with Recurrent Pulled Gastrostomy Tubes

Long-Term Evaluation of Percutaneous Groin Access for EVAR